The global severe hypertriglyceridemia treatment market is experiencing robust growth, with a market value of USD 702.95 million in 2023 and an impressive forecasted growth to USD 2,675.37 million by 2033. This growth trajectory represents a compound annual growth rate (CAGR) of 14.3% from 2023 to 2033. The market’s expansion can be attributed to the rising prevalence of SHTG, coupled with ongoing technological advancements in the development of effective treatments.
Severe hypertriglyceridemia, a condition characterized by extremely high levels of triglycerides in the blood, significantly increases the risk of cardiovascular disease, pancreatitis, and other serious health complications. As the global incidence of SHTG continues to rise, the demand for effective treatments has surged. The market registered a CAGR of 8% in the historical period from 2018 to 2022, signaling a steady increase in the adoption of advanced therapies.
Technological innovations and advancements in the formulation of medications for severe hypertriglyceridemia are further driving market growth. New drug discoveries, particularly those focused on targeted therapies and personalized medicine, are expected to play a key role in expanding treatment options and improving patient outcomes.
Key Market Drivers:
- Increasing prevalence of severe hypertriglyceridemia globally.
- Technological advancements in the manufacturing of medications for SHTG.
- Growing awareness about the importance of early diagnosis and treatment.
As the market continues to evolve, pharmaceutical companies are investing heavily in research and development to bring new, more effective treatment options to market. This trend is expected to propel the market forward, as healthcare providers and patients alike seek advanced, targeted therapies to manage and treat severe hypertriglyceridemia more effectively.
The future of the SHTG treatment market appears promising, with the potential for groundbreaking innovations to shape the industry and improve the quality of life for those affected by this condition.
Key Takeaways from the Market Study
- The global Severe hypertriglyceridemia (SHTG) treatment market is expected to grow with a 14.3% CAGR during 2023 to 2033.
- Hospital pharmacies are expected to hold 40% of the market share in 2023 for Severe hypertriglyceridemia (SHTG) treatment market.
- North America is expected to possess 45% market share for Severe hypertriglyceridemia (SHTG) treatment market in 2023.
- Europe severe hypertriglyceridemia (SHTG) treatment market size is expected to possess 39% market share in 2023.
“As more innovative therapies and drugs are developed, the market for SHTG treatment is likely to become even more competitive, with companies vying for a larger share of the market.” states an FMI analyst
Enhanced Interest in Market Trends: Access In-Depth Analysis and Insights with Our Full Report!
Competitive Landscape
Key players in the severe hypertriglyceridemia (SHTG) treatment market are Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., NorthSea Therapeutics B.V., Amryt Pharma, Afimmune Pharmaceutical, Zucara Therapeutics, Novo Nordisk, Adocia and Pfizer Inc.
- Arrowhead Pharmaceuticals Inc lead drug candidate for SHTG is ARO-APOC3, an RNA interference (RNAi) therapeutic agent designed to target and silence the production of apolipoprotein C-III (APOC3), a protein that plays a key role in regulating triglyceride levels in the blood. In preclinical studies, ARO-APOC3 has been shown to significantly reduce triglyceride levels in animal models of SHTG.
- NorthSea Therapeutics B.V lead drug candidate is called MBOAT7, which is an enzyme that plays a key role in the production of phosphatidylinositol-5-phosphate (PI5P), a lipid that is involved in regulating lipid metabolism. In preclinical studies, MBOAT7 has been shown to reduce triglyceride levels in animal models of SHTG.
Key Segments Profiled in the Severe Hypertriglyceridemia (SHTG) Treatment Market Survey:
Drug Class:
- Olezarsen
- Pegozafermin
- Epeleuton
- Lomitapide
Drug Delivery Method:
- Oral Route
- Injectable Route
Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube